Hepatectomy alters adjuvant anti–PD-1 action in a mouse model of HCC but does not compromise neoadjuvant efficacy
Partial hepatectomy disrupts antitumor immunity and limits adjuvant immune checkpoint inhibitor efficacy. Neoadjuvant anti-PD-1 immunotherapy offers a superior strategy compared with adjuvant immunotherapy in enhancing immune responses and reducing HCC recurrence.
Authors
- Sofia El Hajji (ORCID: https://orcid.org/0000-0002-3028-6148)
- Stéphanie Lacotte (ORCID: https://orcid.org/0000-0002-5921-6389)
- R Bouguerra
- Arnaud Bakaric (ORCID: https://orcid.org/0000-0001-6784-7060)
- Christian Toso (ORCID: https://orcid.org/0000-0003-1652-4522)
- Florence Slits (ORCID: https://orcid.org/0000-0001-7416-6968)
- Laura Rubbia‐Brandt (ORCID: https://orcid.org/0000-0002-3173-3376)
- Beat Moeckli (ORCID: https://orcid.org/0000-0002-9020-8416)
- Charles‐Henri Wassmer (ORCID: https://orcid.org/0000-0002-9018-7088)
Institutions
- University of Geneva (CH)
- University Hospital of Geneva (CH)
- Geneva College (US)
Publication Details
- Journal
- Hepatology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1097/hep.0000000000001575
- Citations
- 3
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 2.39